Sendai virus (SeV) is able to transfect airway epithelial cells efficiently in vivo. However, as with other viral vectors, repeated administration leads to reduced gene expression. We have investigated the impact of inducing immunological tolerance to immunodominant T-cell epitopes on gene expression following repeated administration. Immunodominant CD4 and CD8 T-cell peptide epitopes of SeV were administered to C57BL/6 mice intranasally 10 days before the first virus administration with transmission-incompetent F-protein-deleted DF/SeV-GFP. At 21 days after the first virus administration, mice were again transfected with DF/SeV. To avoid interference of anti-GFP antibodies, the second transfection was carried out with DF/SeV-lacZ.
Introduction
Cystic fibrosis (CF) is a lethal, monogenic disease, caused by mutations in the CF conductance regulator (CFTR) gene. 1 CF is an important candidate for gene therapybased treatments because the median life expectancy is only approximately 30 years and treatment could potentially be administered to the lung noninvasively. CFTR is expressed in the lung in submucosal glands and airway epithelial cells (AECs), 2 the latter likely being the more important target for CF gene therapy. Gene transfer to the airway epithelium via the apical membrane using existing viral and nonviral gene transfer agents (GTAs) is generally inefficient on topical administration. Extracellular barriers such as mucus, mucociliary clearance and glycocalyx proteins limit the access of GTAs to the apical membrane. 3 In addition, the apical membrane of differentiated AECs is relatively devoid of viral receptors, such as those for adenovirus and adenoassociated virus (AAV) type 2. It also has a low basal and stimulated rate of endocytosis, thus discouraging vector entry. Transduction efficiency via the basolateral membrane is generally more efficient, but requires opening of tight junctions, which may not be a clinically viable approach in a disease with a high bacterial load in the lung. Even if the GTA can overcome these extracellular barriers, several intracellular obstacles such as endosomal escape, cytoplasmic trafficking and passage through the nuclear pore complex remain.
We have recently shown that, in contrast to adenovirus and AAV, recombinant Sendai virus (SeV), a murine paramyxovirus, transduces AECs in a variety of animal models efficiently in vivo. 4, 5 Importantly, SeV carrying the CFTR cDNA is able to correct partially the characteristic CFTR-dependent chloride transport defect in the nasal epithelium of CF knockout mice. 6 Several aspects of SeV biology may explain the high gene transfer efficiency into AECs. Importantly, SeV uses cholesterol and sialic acid as receptors. Both are present on the surface of most cell types. Further, SeV requires short contact time with the target cell for internalization, and replicates in the cytoplasm of transduced cells, circumventing the nuclear membrane barrier. Gene expression is transient, with peak expression approximately 48 h after transfection, generally returning to baseline values within 2 weeks of transfection. 7 The mouse is a natural host for SeV and wild-type SeV infection causes pneumonia. It is currently unclear why SeV-mediated gene expression is transient. SeV-induced pulmonary inflammation is dose-and timedependent. At high virus doses accumulation of lymphoid tissue around blood vessels and airways can be observed (J Zhu, personal communication), but elimination of infected cells is unlikely to be the only reason for transient gene expression. If SeV is to be useful in the treatment of a chronic disease such as CF, then sustained or repeated gene expression for the life-time of the patient is required.
Any therapeutic strategy must address the fact that the lung is highly evolved to recognize and eliminate pathogens using a multitude of defense mechanisms. 8 Repeat administration of adenovirus to the lung is not possible, and a variety of strategies to overcome this have been studied. [9] [10] [11] However, the efficient adaptive and innate immune responses have thus far prevented successful readministration (reviewed in Ferrari et al. 12 ). It has been suggested that AAV may be less immunogenic than adenovirus due to the suboptimal ability of the virus to transduce dendritic cells; 13 however, studies have generated conflicting results. [13] [14] [15] [16] [17] During SeV replication, viral proteins are presented on the cell surface of AEC, which can act as antigen-presenting cells. 18, 19 Strategies involving nonspecific immunosuppression to enable repeated SeV administration are not an option in CF because the lungs of patients are chronically infected with pathogenic bacteria. However, we hypothesized that a strategy involving the induction of specific immunological tolerance to components of the SeV might facilitate repeat administration of SeV while leaving other defenses intact.
Since the early days of cellular immunology when it was noted that administration of antigen at very high or low doses could result in specific unresponsiveness, many parameters of tolerance induction have been characterized. 20 Route of administration is one important factor, oral and intranasal pre-administration of soluble peptide having been shown to induce tolerance in murine models of autoimmunity, transplantation and allergy. [21] [22] [23] [24] Induction of tolerance by peptide has also been successfully applied to humans. 25, 26 There has been less impetus to investigate the induction of therapeutic tolerance to eliminate antiviral responses, but a number of examples have been described. [27] [28] [29] Despite the potential complexity of antiviral T-cell responses, the recognition of virus both in mouse models and in humans is often highly focused on a small number of epitopes, making peptide-induced tolerance a realistic possibility. [30] [31] [32] Immunological tolerance may act through a number of different mechanisms, including deletion of reactive clones, anergy through incomplete or altered signalling and regulation by regulatory T cells. Here we evaluate the impact of inducing intranasal tolerance to the CD4 and CD8 immunodominant T-cell epitopes of SeV on gene expression following repeated administration to the airways. This approach is based on the premise that antibody responses (except for rare examples such as the T-cell-independent responses to bacterial polysaccharides) are absolutely dependent on CD4 T-cell help, so that tolerance of T cells should impact also on the neutralizing antibody response.
Results
Repeat administration of DF/SeV to the lung leads to reduced gene expression A schematic diagram illustrating the dosing regime and viral construct used is shown in Figure 1 . To assess the effect of repeat administration of DF/SeV to the lungs, animals were transduced with DF/SeV-GFP on day 0, followed by repeat administration of DF/SeV-lacZ on day 21. b-galactosidase (bgal) expression in lung homogenate was measured 2 days after DF/SeV-lacZ transduction and compared to animals receiving only one administration of DF/SeV-lacZ. Figure 2 shows that although bgal expression levels after repeat administration were still significantly (Po0.005) higher than in untreated mice (n ¼ 22), expression was significantly (Po0.05) reduced by 60% when compared to one administration (n ¼ 22). 
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Intranasal pretreatment with CD4 and CD8 T-cell SeV immunodominant peptide epitopes impacts on T-cell proliferation
In an attempt to improve transfection efficiency after repeat administration of the DF/SeV, animals were pretreated intranasally with either the CD4 or CD8 immunodominant T-cell peptide epitopes to SeV at different doses 10 days before the first virus administration ( Figure 1 ). In the C57BL/6 mouse model of lung immunity to SeV infection, the CD8 T-cell response is highly focused on the nucleoprotein (NP) 324-332 epitope and the CD4 T-cell response on hemaglutinin (HN) 419-433. 30, 33 One control group of mice received an irrelevant T-cell epitope peptide, ovalbumin (OVA) 326-339, while the other control group of mice received no intranasal peptide pretreatment. The administration of SeV vectors to the mice primes T-cell proliferation to the CD4 (NP 324-332) and CD8 (HN 419-433) immunodominant epitopes. Intranasal pretreatment with a single dose of 1 mg/ml of the CD4 immunodominant peptide epitope resulted in a significant (Po0.05) reduction in T-cell proliferation of splenocytes in vitro, relative to the no peptide or the irrelevant peptide control groups. This reduced proliferation (equivalent to 2.470.7-and 1.570.6-fold greater proliferation than in nonantigenexposed controls after challenge with CD4 and CD8 immunodominant epitopes, respectively) was seen when splenocytes were challenged in vitro with 50 mg/ml of either of the CD4 (Figure 3a) or the CD8 (Figure 3b ) immunodominant epitopes.
The reduction in proliferation after challenge with the CD8 epitope in the group of mice pretreated with 1 mg/ ml of the CD4 peptide epitope reflects the dependence of CD8 responses on CD4 T-cell help. Intranasal pretreatment with 1 mg/ml of the CD4, but not the CD8, immunodominant peptide epitope resulted in the induction of T-cell tolerance.
Intranasal pretreatment with CD4 and CD8 T-cell SeV immunodominant peptide epitopes has no impact on anti-SeV neutralizing antibodies
To obtain a functional readout of neutralizing antibody titers, DF/SeV-lacZ virus was pretreated with serum from: (1) untreated mice; (2) mice that had received a single administration of DF/SeV-lacZ; (3) mice that had received a repeat administration of DF/SeV. Virus were then used to infect HeLa cells. A representative graph is shown in Figure 4a . At low serum dilutions, all the mice that had received two doses of DF/SeV produced antiSeV neutralizing antibodies and showed reduced transfection of HeLa cells. The transduction efficiency was restored by subsequent serum dilutions. In contrast, serum from untreated control mice and mice receiving only one administration of DF/SeV (serum collected two days after transduction) did not produce any neutralizing antibodies. In Figure 4b , the serum dilution at which 50% of bgal expression of the untreated control mice was reached is plotted. There was no significant difference in neutralizing antibody measurements between the groups. In contrast to the reduced T-cell proliferation following pretreatment with intranasally-administered peptide, there was no evidence of any reduction in the neutralizing antibody titer indicating 'split tolerance'.
Intranasal pretreatment with CD4 and CD8 T-cell SeV immunodominant peptide does not improve levels of gene expression after repeat administration of DF/SeV
To assess the effect of tolerization on repeat administration, bgal expression was measured in lung homogenate 2 days after the second DF/SeV transfection. Peptide preadministration did not improve gene expression. Indeed, bgal expression was reduced in mice that had a reduction in T-cell proliferation after immunization H-thymidine incorporation data were standardized by calculating the relative ratio compared to the no peptide control group. The relative proliferation in the presence of 50 mg/ml of the CD4 (a) and CD8 (b) immunodominant epitope to SeV is shown. Groups of mice were administered the concentrations shown of the CD4 or CD8 immunodominant epitopes, control peptide or no peptide to the lungs on day À10 prior to transfection with DF/SeV. Data were normalized to the no peptide control group and presented as mean7s.e.m. *Po0.05 when compared to no peptide or irrelevant peptide control group (n ¼ 6-12/group).
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Discussion
Administration of viral vectors to the lung must overcome the significant hurdle of highly evolved immune mechanisms that exist to recognize and eliminate pathogens. 8 As expected, we show here that bgal expression after repeat administration of recombinant DF/SeV-lacZ is comparatively inefficient due to potent immune responses to the vector. We, therefore, assessed the effect of tolerance induction to the immunodominant CD4 and CD8 epitopes from SeV and showed that, despite achieving a reduction in T-cell proliferation via the CD4 epitope, there was no reduction of anti-SeV neutralizing antibodies or increase in gene expression.
Nonviral GTAs are less efficient in transfecting AECs than viral vectors. However, viral GTAs are immunogenic and a significant reduction in gene expression after repeat administration has previously been reported for commonly used viral GTAs such as adenovirus and AAV, and is due to the generation of immune responses against viral proteins. First-generation recombinant SeV retains all viral genes, 35 and are transmission-competent. Secondgeneration, attenuated, nontransmissable SeV has been generated by deleting the F protein (DF/SeV) required for viral entry into the cell. 36 We have demonstrated that second generation DF/SeV is as efficient as first-generation viruses in transfecting AECs. 7 Following transduc- Immune tolerance to Sendai virus U Griesenbach et al tion, DF/SeV replicates in the cytoplasm and, although the F protein-deleted second-generation DF/SeV is transmission-incompetent, viral proteins are incorporated into the cell membrane of the infected cell and virus-like noninfective particles are released from the cells. Third-generation SeV vectors have been further depleted of the HN and M proteins, but the remaining viral proteins (NP, P, L) cannot be deleted, because they are essential for recombinant protein production. 37 Importantly, however, the complete removal of all viral proteins from adenoviral vectors has not improved their capacity for repeat administration. 38 Alternative strategies to enable repeat administration of SeV clearly need to be developed. Nonspecific immune suppression is not clinically desirable in CF, particularly in the context of SeV gene therapy, which would require prolonged immune suppression for the duration of SeV-mediated gene expression, because of the persistent virus replication. Specific tolerization of CF patients to SeV, which is not a human pathogen, however, might be a clinically feasible option. The induction of specific immunological tolerance is a manipulation that has been successfully applied in a number of other experimental and clinical settings. 26, 27 A wide variety of strategies have previously been investigated for the induction of effective immunological tolerance against viral antigens. While the goal in most systems is to promote antiviral immunity, such responses may be undesirable when they lead to loss of therapeutic gene expression as shown here, or when the response is itself associated with excessive immunopathology. 28, 39 Immunological tolerance to viruses has previously been achieved by administration of tolerogenic peptides, 28, 40 by oral administration of antigen, 41 by giving virus under the cover of either anti-CD4 or anti-CD40L antibody, 39 or by giving apathogenic virus intravenously. 27, 42 While neonatal administration of virus might be expected to induce tolerance, this can alternatively lead in some cases to highly efficient priming of responses. More robust tolerance may be achieved through neonatal expression, which is specifically targeted to the thymus. 29 However, this approach raises concerns about the ease of translation to clinical practice. In light of these considerations, we decided to investigate peptide-induced tolerance, which has a strong track record of translation to the clinic in a range of diseases. 26, 43 While there are theoretical concerns that it might not be possible to achieve immunological tolerance to a complex set of viral antigens through administration of a single epitope, analysis of viral immune responses suggests that T cells often focus on a rather small number of immunodominant epitopes. 44 Furthermore, peptides are relatively cheap to prepare, easily administered and well tolerated.
A large body of work by David Woodland and others on protective immunity against SeV indicates a vital role of T cells. 45, 46 We, therefore, administered CD4 and CD8-immuno dominant SeV epitopes to the lungs of mice 10 days before DF/SeV. While tolerance experiments in mouse models have tended to rely on a form of 'highdose' tolerance at 100 mg or greater, 23, 47 we found, in line with recent findings from clinical studies, 25 that tolerance was actually induced after a single dose of 1 mg peptide, and not at higher doses. Interestingly, a single tolerizing dose of the CD4 epitope largely abrogated not only the response of T cells to this epitope, but also to the immunodominant CD8 class I restricted epitope, presumably because the latter response is dependent on help from CD4T cells. Despite reasonably robust T-cell tolerance, we obtained no evidence for enhanced levels of gene expression from repeat virus administration. The most likely explanation for this is that we generated 'split tolerance' that left neutralizing antibody titers unaltered, and elimination of repeat virus administration was here Figure 5 bgal expression after repeated administration of DF/SeV following pretreatment using intranasal CD4 and CD8 immunodominant T-cell epitopes to SeV. To assess the effect of peptide tolerization on gene transfer efficiency after repeat administration, peptide was administered to the lungs of mice in a single bolus of 100 ml using the standard 'sniffing' procedure on day À10. Mice were transfected with DF/SeV-GFP on day 0 and with DF/SeV-lacZ on day 21. Lungs were harvested 2 days after DF/SeV-lacZ transfection and bgal expression analyzed. Data were normalized to the no peptide control group and presented as mean7s.e.m. Please refer to Figure 2 for absolute bgal expression values. The no peptide control group is identical to the repeat administration group in Figure 2 . Please refer to *Po0.05 when compared to no peptide control group, n ¼ 12/group.
Immune tolerance to Sendai virus U Griesenbach et al achieved through antibody neutralization of input virions. 'Split tolerance', affecting one component of the immune system, but not others, is a frequent observation in viral systems, presumably because a multi-layered immune response against pathogenic viruses has been a strong evolutionary driving force. 27, 48 How could an effective neutralizing antibody response develop in the face of a strong reduction in the peptide-specific CD4 helper T-cell response? One possibility is that there is sufficient, residual T-cell effector function available to supply a low level of cytokine support for the B-cell response. Another possibility is that, as a result of peptide-specific tolerance induction, the antiviral response shifts to subdominant epitopes. Analysis of these hypotheses will require further investigation. Even if one could achieve absolute tolerance with respect to the antibody and T-cell limbs of the adaptive immune response, there is still the likelihood of an efficient, or even an enhanced response using other mechanisms, for example, natural killer (NK) 1.1 T cells. 49 Thus, Scaria et al. 50 have demonstrated previously that inhibition of cytotoxic T cells (CTLs) through overexpression of ICP47, a protein that prevents MHC class I-mediated antigen presentation to CD8 T cells, leads to an increased activation of NK cells. Indeed, in our study, elimination of bgal viral expression appears enhanced in the presence of split tolerance. This is an important caveat for immunomodulation initiatives: compensatory mechanisms including NK cells that replace the normal, adaptive T-cell response may be even more potent.
In conclusion, induction of tolerance using an immunodominant CD4 peptide epitope does not allow more efficient gene expression following a second administration of a SeV vector.
Materials and methods
Peptide and recombinant SeV preparation
Peptides were synthesized on a 20-40 mg scale (BioSynthesis Incorporated, Lewisville, TX, USA) and arrived lyophilized. [(CD4 epitope -SeV HN protein 419-433): NH2-VYIYTRSSGWHSQLQIG-OH, (CD8 epitope -SeV NP protein 324-332): NH2-FAPGNYPAL-OH, control peptide epitope OVA 326-339: NH2-AVHAA-HAEINEAGR-OH]. The peptides were dissolved in dimethyl sulfoxide (DMSO, Sigma) and stored at a concentration of 75 mg/ml at À801C. Final working concentrations of peptide for experimental use were made up on the day using PBS.
The generation and propagation of the recombinant DF/SeV vector carrying a green fluorescent protein (DF/ SeV-GFP) or a lacZ reporter gene (DF/SeV-LacZ) was carried out as described previously. 4 The supernatant of LLC-MK2/F7 cells containing infectious particles was subsequently purified, concentrated and stored at À801C. Virus titer was determined by infecting LLC-MK2 cells and counting the number of bgal or GFP-expressing cells. For both viruses, the titer was expressed as Cell Infectious Units (CIU) per ml.
Administration of peptide and virus to mouse lung C57BL/6 mice (female 6-10 weeks) were anesthetized with metophane (Medical Developments Australia Pty Ltd, Springvale, Australia) and the peptide (1, 10 or 100 mg in 100 ml PBS) was placed as a single bolus into the nasal cavity and the solution rapidly 'sniffed' into the lungs. At 10 days after peptide administration, mice were transduced with DF/SeV-GFP (10 6 CIU/mouse in 100 ml PBS), and 21 days later with DF/SeV-lacZ (10 7 CIU/ mouse in 100 ml PBS) using the 'sniffing' technique. Control groups receiving no virus or one administration of DF/SeV-lacZ were included. At 2 days after the last virus administration, all animals were culled. Lungs from individual mice were snap-frozen in liquid nitrogen and stored at À801C for bgal quantifiaction. Spleens from individual mice were harvested for T-cell proliferation assays. Blood was collected and stored at 371C for a minimum of 2 h. After clotting, the blood was spun at 4000 r.p.m. for 10 min and serum was frozen at À801C for anti-SeV neutralizing antibody measurements.
T-cell proliferation
Spleen cells were disaggregated using fine gauge needles, resuspended in HL1 serum-free medium (Hycor Biomedical, Irvine, CA, USA) supplemented with L-glutamine (2 mM), 2-mercaptoethanol (5 Â 10 H-thymidine incorporation data were standardized by calculating the relative ratio compared to the no peptide control group.
Neutralizing antibody assay
HeLa cells (2500 per well in a 96-well plate) were seeded 1 day before transfection. Serum was heat-inactivated for 40 min at 551C and 1:2 serial dilutions in DMEM (+1% FCS +1% penicillin/streptomycin) prepared (1:2-1:8192). DF/SeV-LacZ (5 Â 10 4 CIU) was added to each serum dilution and incubated at 371C for 1 h in an incubator (5% CO 2 ). Following the incubation, the medium is removed from the HeLa cells and replaced with the 100 ml of the serum dilutions containing the virus. Cells were incubated for 5 h at 371C, after which the serum was removed and replaced with normal growth medium (DMEM+10% FCS and 1% penicillin/streptomycin). At 24 h after transfection the medium was removed, cells are washed with PBS and lysed with 120 ml Universal lysis buffer (Roche), freeze/thawed three times, and frozen at À801C. bgal protein expression was quantified in homogenates using the luminescent bgal Reporter System 3 (Clontech, UK) according to the manufacturer's recommendations.
Reporter gene assay
Lungs were homogenized in 300 ml Universal lysis buffer (Roche), freeze/thawed three times, spun at 10 000 r.p.m. for 10 min and supernatant was frozen. bgal protein expression was quantified in lung homogenates using the luminescent bgal Reporter System 3 (Clontech, UK) according to the manufacturer's recommendations. Total protein was quantified using the DC Protein Assay Kit Immune tolerance to Sendai virus U Griesenbach et al (BioRad Herts, UK) according to the manufacturer's recommendations and expressed as pg bgal/mg total protein. Data were then normalized, by calculating the relative ratio compared to the no peptide control group, which was arbitrarily set to one.
Statistical analysis
All values are expressed as mean7s.e.m. for convenience. Individual data points are shown as diamonds, with the mean indicted by a bar. N refers to the number of animals used. The independent-sample Student t-test was used after confirmation of normal distribution (Figure 2) or Wilcoxon sign-rank test (Figures 3 and 5) . The null hypothesis was rejected at Po0.05.
